This document discusses efforts to accelerate research for rare disease MPSIIIC through open science and partnerships. An organization called Jonah's Just Begun is partnering with scientists, clinicians, other patient groups, and a company called Phoenix Nest to pursue multiple treatment approaches including gene therapy, substrate reduction, and mutation correction. Early diagnosis of the main patient Jonah allowed early intervention and the formation of a global network to share knowledge and accelerate research that may find treatments in his lifetime. Open data sharing, patient engagement, and disrupting traditional models are seen as ways to further progress. Support is needed for increased awareness, diagnostics, and funding to move the efforts beyond the current scope.
A presentation summarising the process of developing an entry-level phenotype for case ascertainment in genetic studies of neuropathic pain. The presentation was made at the 5th International Congress on Neuropathic Pain, Nice, France, 2015.
Why there needs to be open data for ultra-rare and rare disease drug discoverySean Ekins
ACS presentation 11th Aug San Francisco on the need for open data in ultra rare and rare diseases. Describes efforts of parent/ patient advocates to fund drug discovery research. Also it describes software for open collaboration and what needs to be done to create software champions for rare diseases. Mentions diseases like Sanfilippo Syndrome, giant axonal neuropathy and Charcot Marie Tooth. Apps like ODDT are also mentioned as a means to share data.
A Call to Action: Improving brain & mental health via digital platforms,...SharpBrains
(Session held at the 2014 SharpBrains Virtual Summit; October 28-30th, 2014)
8:15–9:45am. A Call to Action: Improving brain & mental health via digital platforms, neuroplasticity research and the White House BRAIN initiative
- Dr. Thomas Insel, Director of the National Institute of Mental Health (NIMH)
- Dr. Adam Gazzaley, Director of UCSF Neuroscience Imaging Center and Co-founder of Akili Interactive Labs
- Dr. Daphne Bavelier, Head of the Brain & Learning Lab at the University of Geneva & U. of Rochester
- Jack Young, Head of Qualcomm Life Fund
- Chair: Alvaro Fernandez, CEO of SharpBrains
Learn more here:
http://sharpbrains.com/summit-2014/agenda/
A presentation summarising the process of developing an entry-level phenotype for case ascertainment in genetic studies of neuropathic pain. The presentation was made at the 5th International Congress on Neuropathic Pain, Nice, France, 2015.
Why there needs to be open data for ultra-rare and rare disease drug discoverySean Ekins
ACS presentation 11th Aug San Francisco on the need for open data in ultra rare and rare diseases. Describes efforts of parent/ patient advocates to fund drug discovery research. Also it describes software for open collaboration and what needs to be done to create software champions for rare diseases. Mentions diseases like Sanfilippo Syndrome, giant axonal neuropathy and Charcot Marie Tooth. Apps like ODDT are also mentioned as a means to share data.
A Call to Action: Improving brain & mental health via digital platforms,...SharpBrains
(Session held at the 2014 SharpBrains Virtual Summit; October 28-30th, 2014)
8:15–9:45am. A Call to Action: Improving brain & mental health via digital platforms, neuroplasticity research and the White House BRAIN initiative
- Dr. Thomas Insel, Director of the National Institute of Mental Health (NIMH)
- Dr. Adam Gazzaley, Director of UCSF Neuroscience Imaging Center and Co-founder of Akili Interactive Labs
- Dr. Daphne Bavelier, Head of the Brain & Learning Lab at the University of Geneva & U. of Rochester
- Jack Young, Head of Qualcomm Life Fund
- Chair: Alvaro Fernandez, CEO of SharpBrains
Learn more here:
http://sharpbrains.com/summit-2014/agenda/
A presentation given by Prof. David Croaker & Eunice Gribben at the CHA Cofnerence in October 2012, The Journey, in the 'innovations in supporting chronically unwell children, young people and their families' stream.
Sharing of data leads to progress on alzheimers.docStudioHOF
The need was for all researchers and experts to come together to work and evolve a standard data set. But how was this possible? It would entail an incredible collaboration as no one company or researcher could manage to do this alone.
Why aren’t we solving the greatest scientific problems of the world today? Innovation is critical to our nation’s scientific enterprise. However, creative thinking has been on the decline and is not generally taught in academic institutions. Renowned public health scientist and clinician, Dr. Roberta Ness, Dean of the University of Texas Health School of Public Health, believes that students, established scientists, researchers, and engineers can learn to be more innovative. Through her book Innovation Generation: How to Produce Creative and Useful Scientific Ideas, and graduate course on Innovative Thinking at the University of Texas, Dr. Ness provides the framework and tools to “think outside the box.” She shared these basic concepts in this one-hour lecture. Dr. Ness is a leading researcher in women’s health and widely known for her efforts to bridge from research to policy. She is a member of the Institute of Medicine.
The Arthritis National Research Foundation is the only charity solely focused on funding arthritis research to cure arthritis. With your help this arthritis foundation can support more arthritis research and find a cure. Please make a donation or get involved today!
Growing Stronger Research Fund Overview Jan 2012 For DonorsAmer Haider
Website: http://www.growingstroner.org.
Overview of http://www.GrowingStronger.org, a non-profit focused on improving the quality of life of little people through supporting medical research.
PERSONALISED MEDICINE: Use of Personalised Medicine in the prevention of disease and the maintenance of wellness
THE ENIGMA OF THE THRACIANS AND THE ORPHEUS MYTH: Journey to the Past Orphic Mysteries
, AND THE LORD OF THE NIGHT SKY: Observe top spring objects with a robotic telescope from home
Down Syndrome Cognition Research 101: An Introductionplus15campaign
An introduction to topics in Down syndrome cognition research, including current initiatives DSRTF supports and clinical trials now underway. Presenters: DSRTF board member Sarah Wernikoff; DSRTF Chief Scientific Officer Dr. Michael Harpold; and Roche Pharmaceuticals' Dr. Omar Khwaja.
Presentation from AAPS PharmSci360 (October 23, 2023) in which I describe highlights of my Springer/AAPS book Winning Grants (https://link.springer.com/book/10.1007/978-3-031-27516-6) - presenting a 'how to' guide on writing small business grants - e.g. NIH STTR and SBIR grants. Written by someone experienced in winning such grants.
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...Sean Ekins
The presentation was given at SETAC 2022 Nov 16 and describes our work on Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic Toxicity.
We generated many models that are available to license in our MegaTox software. We found that the support vector machines performed the best after assessing many algorithms for both classification and regression models.
The authors of this work are Thomas R Lane, Fabio Urbina and Sean Ekins.
The contact is sean@collaborationspharma.com
More Related Content
Similar to Disrupting drug discovery one disease at a time
A presentation given by Prof. David Croaker & Eunice Gribben at the CHA Cofnerence in October 2012, The Journey, in the 'innovations in supporting chronically unwell children, young people and their families' stream.
Sharing of data leads to progress on alzheimers.docStudioHOF
The need was for all researchers and experts to come together to work and evolve a standard data set. But how was this possible? It would entail an incredible collaboration as no one company or researcher could manage to do this alone.
Why aren’t we solving the greatest scientific problems of the world today? Innovation is critical to our nation’s scientific enterprise. However, creative thinking has been on the decline and is not generally taught in academic institutions. Renowned public health scientist and clinician, Dr. Roberta Ness, Dean of the University of Texas Health School of Public Health, believes that students, established scientists, researchers, and engineers can learn to be more innovative. Through her book Innovation Generation: How to Produce Creative and Useful Scientific Ideas, and graduate course on Innovative Thinking at the University of Texas, Dr. Ness provides the framework and tools to “think outside the box.” She shared these basic concepts in this one-hour lecture. Dr. Ness is a leading researcher in women’s health and widely known for her efforts to bridge from research to policy. She is a member of the Institute of Medicine.
The Arthritis National Research Foundation is the only charity solely focused on funding arthritis research to cure arthritis. With your help this arthritis foundation can support more arthritis research and find a cure. Please make a donation or get involved today!
Growing Stronger Research Fund Overview Jan 2012 For DonorsAmer Haider
Website: http://www.growingstroner.org.
Overview of http://www.GrowingStronger.org, a non-profit focused on improving the quality of life of little people through supporting medical research.
PERSONALISED MEDICINE: Use of Personalised Medicine in the prevention of disease and the maintenance of wellness
THE ENIGMA OF THE THRACIANS AND THE ORPHEUS MYTH: Journey to the Past Orphic Mysteries
, AND THE LORD OF THE NIGHT SKY: Observe top spring objects with a robotic telescope from home
Down Syndrome Cognition Research 101: An Introductionplus15campaign
An introduction to topics in Down syndrome cognition research, including current initiatives DSRTF supports and clinical trials now underway. Presenters: DSRTF board member Sarah Wernikoff; DSRTF Chief Scientific Officer Dr. Michael Harpold; and Roche Pharmaceuticals' Dr. Omar Khwaja.
Presentation from AAPS PharmSci360 (October 23, 2023) in which I describe highlights of my Springer/AAPS book Winning Grants (https://link.springer.com/book/10.1007/978-3-031-27516-6) - presenting a 'how to' guide on writing small business grants - e.g. NIH STTR and SBIR grants. Written by someone experienced in winning such grants.
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...Sean Ekins
The presentation was given at SETAC 2022 Nov 16 and describes our work on Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic Toxicity.
We generated many models that are available to license in our MegaTox software. We found that the support vector machines performed the best after assessing many algorithms for both classification and regression models.
The authors of this work are Thomas R Lane, Fabio Urbina and Sean Ekins.
The contact is sean@collaborationspharma.com
A presentation at the Global Genes rare drug development symposium on governm...Sean Ekins
This presentation from June 12 2020 gives a brief overview of my experience of 15 years of applying for government grants to fund small companies. Prior to this I had no experience of applying for such grants. The bottom line for rare disease groups / families is find a scientist that can do this or assist you. please also see www.collaborationspharma.com
Leveraging Science Communication and Social Media to Build Your Brand and Ele...Sean Ekins
Slides from AAPS Careers session by Maren Katherina Preis, Kyle Bagin, Sean Ekins
Provides some clear steps on how you could use social media to help your career.
Oral presentation given in MEDI session at 2017 ACS in DC.
co-authors Kimberley M. Zorn, Mary A. Lingerfelt, Jair L. de Siqueira-Neto, Alex M. Clark, Sean Ekins
describes drug repurposing and machine learning - for more details see www.collaborationspharma.com
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...Sean Ekins
Oral presentation at 2017 ACS in DC - given by Kimberley Zorn
co-authors include Mary A. Lingerfelt, Alex M. Clark, Sean Ekins
for more details see www.collaborationspharma.com
Five Ways to Use Social Media to Raise Awareness for Your Paper or ResearchSean Ekins
Presentation given at the AAPS 2016 conference in Denver. Some of the slides are from AAPS, Some from Kudos and some from Figshare. One slide is from Tony Williams. All slides used with permission.
CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...Sean Ekins
A perspective on 12 yrs of CDD and developing products and collaborations.
A presentation given at the ACS meeting in San Diego - small business section
This presentation summarizes some early efforts on an open drug discovery collaboration between scientists in Brazil and the US. The amazing virus images were created by John Liebler and can be licensed from him http://www.artofthecell.com/animation/will-the-real-zika-virus-please-stand-up
The homology models were created with Swiss Model by Sean Ekins:
Marco Biasini, Stefan Bienert, Andrew Waterhouse, Konstantin Arnold, Gabriel Studer, Tobias Schmidt, Florian Kiefer, Tiziano Gallo Cassarino, Martino Bertoni, Lorenza Bordoli, Torsten Schwede. (2014). SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Research; (1 July 2014) 42 (W1): W252-W258; doi: 10.1093/nar/gku340.
Arnold K., Bordoli L., Kopp J., and Schwede T. (2006). The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics, 22,195-201.
Kiefer F, Arnold K, Künzli M, Bordoli L, Schwede T (2009). The SWISS-MODEL Repository and associated resources. Nucleic Acids Research. 37, D387-D392.
Guex, N., Peitsch, M.C., Schwede, T. (2009). Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. Electrophoresis, 30(S1), S162-S173.
Ensuring Chemical Structure, Biological Data and Computational Model Quality
A talk given at SLAS 2016 mon Jan 25th in San Diego
covers published work and recent forays with BIA 10-2474
Pros and cons of social networking for scientistsSean Ekins
Over the past 4 years I have been using social networking tools for scientists more inspired by Antony Williams. I realized I am using many tools and there are pros and cons of them. Here is my brief summary.
CDD: Vault, CDD: Vision and CDD: Models for Drug Discovery CollaborationsSean Ekins
A talk given at SERMACS 7th Nov 2015 in Memphis, describes CDD Vault, CDD Vision and CDD Models. In addition it also describes how the software is used in large and smaller scale collaborations for drug discovery.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
1. Disrupting Drug Discovery
– one rare disease at a time
• Jill Wood, Jonah’s Just Begun
• Sean Ekins, Phoenix Nest, Inc.
2. Jonah Wood Weishaar DOB 7/30/08
DX’d MPSIIIC 5/6/2010
Jonah was born happy and
healthy, with no complications.
He was A-symptomatic at the
time of DX and he still is,
but the clock is ticking...
3. A-Typical Diagnosis
New Pediatrician noted large head and suggested MRI.
MRI done at NYU, currently conducting ERT trial for MPSII.
MRI showed skull deformity consistent with MPS.
Geneticist tested for which MPS. Took 6 weeks from time of
MRI to final dx.
On avg. MPSIIIC children are dx’d at 6 years of age, when
cognitive skills slow down.
4. Proactive Clinicians
gave us the resources to hit the ground running...
“No this does not have to be a death
sentence.” “Cures that were thought
impossible just a few years ago are a reality
today.”
- David Karen, New York Methodist
• Pub Med Search
Found papers on Sanfilippo and called the authors.
Met scientists in person and established our scientific team.
Thanks to our diagnosis team:
• MPS Society
Member Registry, helped build our patient populations -Dr. Hai Cao, pediatrician, Southslope Pediatrict’s,
Media blitz, clinicians and FB built the rest of our PP -Dr. Romaine Schubert, Neurologist NYM
• Clinician Referalls -Dr. David Karen, Geneticist NYM
Created our scientific advisory board -Erin Carney, Genetic Counselor NYM
Hosted our first patient population meeting.
Where we identified the most relevant approaches: get the
enzyme back in, remove the substrate or fix the mutation.
5. Partnering with: SAB & Clinicians
Find your patient population.
Locate the scientists interested in
MPSIII.
Prepare for your NHS.
We did all these things....
Reach out to supporting Our first patient population meeting was held at
Columbia Presbyterian, with JJB’s SAB.
organization’s.
Host a Patient Population meeting. We identified three approaches: get the enzyme
back in, reduce the substrate or fix the
mutation.
6. Partnered with like minded parents
JLK-Sanfilippo Sanfilippo Barcelona,
Research Foundation Spain
Jonah’s Just Sanfilippo Sud,
Begun France
7. Partnered with Scientists
Scientist Science
Alexey Pshezhetsky, Canada AAV gene therapy, Chaperones (missense
and splicesite), Novel (upregulation)
Brian Bigger, UK AAV gene therapy
Daniel Grinberg, Spain Correction of nonsense mutations
Alessandro Fraldi, Italy Novel (optimized fusogenic liposomes)
Andrea Ballabio, Italy TFEB
Jerome Ausille, France Novel
8. Partnering with other Organizations
My Support Staff....
Partnering 4 Cures
RARE Global Genes Project
RDLA EveryLife Foundation
Open Drug Discovery Teams
MPS Societies
While waiting for the science.
Remove the other obstacles,
leading to faster trial’s.
9. Early Diagnosis gave us
Early Intervention & Prevention
Upon DX, we placed tubes in Jonah’s ears, preventing hearing
loss.
Speech therapy brought Jonah’s language to where it should
be.
We now know to watch for serious medical issues.
We had a 25% chance of having a second sick child.
Jonah remains the youngest child diagnosed with MPSIIIC.
Because of Jonah, the World has research for potential
treatments for MPSIIIC.
Jonah will now see a treatment in his life time
10. Partnering at P4C 2011
Sean has helped by:
Encouraging me to create a virtual biotech.
Writing SBIR grants with JJB’s scientists.
Reviewing our research, finding new ways to increase
productivity.
Forcing the issue of open science, through his work
with ODDT.
Bringing more exposure to JJB through publications
12. Phoenix Nest
SAB BOD
• Robert Steiner, (Oregon Health • Jill Wood, (CEO)
and Science University) Bernard Munos, (Founder InnoThink)
Elsa Shapiro, (Professor, Nicole Boice, (Children’s RARE Disease
Network )
Neuropsychology Director, Renée J. G. Arnold, PharmD, RPh (IMS
University of Minnesota) Consulting Group)
Ozlem Goker-Alpan, (O&O Alpan, Joseph Corkery, (VP, Business
LLC) Development, OpenEye)
Alexey Pshezhetsky, (Prof, Graciana Diez-Roux, (Chief Scientific
Officer and PhD Programammes Dean,
University of Montreal) TIGEM)
Brian Bigger, (Senior Research
Fellow, University of Manchester)
14. Can we foster:
Disruption
• #1: NIH and other international scientific funding bodies
should mandate …open accessibility for all data generated
by publicly funded research.
• #2: Reboot the pharmaceutical industry by extending the
notion of ‘‘precompetitive’’ collaboration to encompass
later stages of research to allow PPPs to flourish.
• #3: FDA takes a proactive role in making relevant clinical
data available that will help all drug developers (as well as
NCATS) to bridge the valley of death and remove a
bottleneck.
• #4: Companies listen to the patients as they generate data
on social media, mine it for indications and off target
effects. Companies and funding bodies will find the
innovators to exploit this information and use
collaborative tools to share data
15. We developed an iOS mobile app (ODDT) to get visibility and
share knowledge *
*With Alex Clark (Molecular
Materials Informatics)
Mol Informatics, 31: 585-597, 2012
Drug Discovery Today, In press.
16. What we need from you
Remove barriers to finding more patients.
There is no newborn screening for MPSIIIC
There is no global registry for this disease
Facilities that can test for and dx patients can't refer the patients to centers of
excellence, where they can be added to a registry, receive the healthcare
they need or connect with other patients.
Funding for Research
NIH funding is not easily tapped into when all of your investigators are foreign.
Growth
To get off the kitchen table, JJB needs funding for additional fundraising staff
JJB driven by one unpaid, FTE - Jill
JJB and Phoenix Nest could accomplish more with bigger paid staff
What we need from you
We need at least a years funding for a CSO to coordinate research, identify and
remove the obstacles, find CRO's, build equity etc.
We need a financial adviser to advise on PN's business development